Athira Pharma Past Earnings Performance
Past criteria checks 0/6
Athira Pharma's earnings have been declining at an average annual rate of -52.3%, while the Pharmaceuticals industry saw earnings growing at 1% annually.
Key information
-52.3%
Earnings growth rate
-16.6%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | n/a |
Return on equity | -90.4% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?
Feb 16Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
Nov 02Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
May 29Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?
Jan 04Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis
Oct 17Athira Pharma GAAP EPS of -$0.65
Aug 15We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely
Aug 09Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug
Jun 22Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth
May 08We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate
Jan 11Athira Pharma: What, Exactly, Did The CEO Do?
Jun 29Athira Pharma falls after the decision to place CEO on temporary leave
Jun 17Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy
Jun 07We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth
May 24We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely
Feb 08Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach
Jan 11Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like
Dec 18Athira Pharma nabs research grant of $15M from NIH
Dec 08Athira Pharma reports Q3 results
Nov 12Revenue & Expenses BreakdownBeta
How Athira Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -118 | 33 | 94 |
30 Sep 23 | 0 | -121 | 34 | 85 |
30 Jun 23 | 0 | -108 | 33 | 75 |
31 Mar 23 | 0 | -102 | 32 | 68 |
31 Dec 22 | 0 | -96 | 33 | 61 |
30 Sep 22 | 0 | -82 | 31 | 59 |
30 Jun 22 | 0 | -77 | 31 | 53 |
31 Mar 22 | 0 | -67 | 27 | 50 |
31 Dec 21 | 0 | -55 | 21 | 43 |
30 Sep 21 | 0 | -46 | 19 | 35 |
30 Jun 21 | 0 | -39 | 13 | 30 |
31 Mar 21 | 0 | -27 | 9 | 20 |
31 Dec 20 | 0 | -20 | 7 | 13 |
30 Sep 20 | 0 | -13 | 3 | 9 |
30 Jun 20 | 0 | -6 | 2 | 4 |
31 Mar 20 | 0 | -6 | 2 | 3 |
31 Dec 19 | 0 | -5 | 2 | 4 |
Quality Earnings: ATHA is currently unprofitable.
Growing Profit Margin: ATHA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ATHA is unprofitable, and losses have increased over the past 5 years at a rate of 52.3% per year.
Accelerating Growth: Unable to compare ATHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATHA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: ATHA has a negative Return on Equity (-90.39%), as it is currently unprofitable.